Novaremed

Executive Summary

Novaremed AG is a private, clinical-stage biopharmaceutical company based in Basel, Switzerland, developing non-opioid therapies for chronic pain and peripheral neuropathy. Its lead candidate, nispomeben, is a non-opioid small molecule in a Phase 2b trial for painful diabetic peripheral neuropathy (PDPN), with FDA Fast Track designation. The company also has MP-101, a Phase 2 candidate for preventing chemotherapy-induced peripheral neuropathy (CIPN). With a growing global need for safer pain alternatives, Novaremed targets a significant market. However, as a private company with limited public disclosures, the near-term outlook depends on clinical execution and funding. The company's focus on non-opioid mechanisms positions it well if it can demonstrate efficacy and safety in ongoing trials.

Upcoming Catalysts (preview)

• TBDPhase 2b top-line data for nispomeben in PDPN35% success
• TBDPhase 2 initiation or interim data for MP-101 in CIPN25% success